BD (NYSE:BDX) today shared the results from a preliminary study investigating the impact of deep cold storage on glass prefillable syringes. Franklin Lakes, N.J.-based BD's study evaluated deep cold storage (-20°C and -40°C) as traditional vaccine … [Read More...] about BD says glass prefillable syringes still perform after deep cold storage
Main Content
Sponsored Content
Noble expands its services for its clients into Human Factors
Human Factors + (HF+) is a natural extension of Noble’s deep understanding of the patient experience relative to self-administering drug therapies By Tim McLeroy, Executive Director of Marketing … [Read More...] about Noble expands its services for its clients into Human Factors
Featured Posts
Thermo Fisher authorizes $3B in share repurchases
Thermo Fisher Scientific (NYSE:TMO) yesterday announced authorization for the repurchase of $3 billion in common stock shares. Waltham, Massachusetts-based Thermo Fisher's board of directors approved the repurchase of $3 billion in shares of its … [Read More...] about Thermo Fisher authorizes $3B in share repurchases
FDA approves Baxter’s norepinephrine injection for treating low blood pressure
Baxter (NYSE:BAX) announced today that it received FDA approval for its premix norepinephrine bitartrate in 5% dextrose injection. Deerfield, Illinois-based Baxter launched the norepinephrine injection following the approval for raising blood … [Read More...] about FDA approves Baxter’s norepinephrine injection for treating low blood pressure
Merck and Vesselon preclinical study reports dramatic tumor pharmacokinetics findings
Merck & Co. (NSDQ:MRNA) scientists have explored fighting cancer by way of the STING (stimulator of interferon genes)-controlled innate immune pathway. Now, the company has published research in Advanced Therapeutics detailing a preclinical … [Read More...] about Merck and Vesselon preclinical study reports dramatic tumor pharmacokinetics findings
BD says glass prefillable syringes still perform after deep cold storage
BD (NYSE:BDX) today shared the results from a preliminary study investigating the impact of deep cold storage on glass prefillable syringes. Franklin Lakes, N.J.-based BD's study evaluated deep cold storage (-20°C and -40°C) as traditional vaccine … [Read More...] about BD says glass prefillable syringes still perform after deep cold storage
Welldoc wins expanded FDA clearance for BlueStar insulin dosing platform
Welldoc announced today that it received another FDA 510(k) clearance for its BlueStar diabetes treatment platform. Columbia, Maryland-based Welldoc's new clearance for BlueStar — the ninth in total — expands insulin dosing support to most types … [Read More...] about Welldoc wins expanded FDA clearance for BlueStar insulin dosing platform
IVX Health raises $100M to accelerate expansion for infusion centers
IVX Health announced today that it completed a $100 million Series F minority investment round from Great Hill Partners. Nashville, Tennessee-based IVX plans to utilize the funding to accelerate its entry into new markets in 2022 and beyond in its … [Read More...] about IVX Health raises $100M to accelerate expansion for infusion centers
FDA approves first Lucentis injection biosimilar for treating eye diseases
The FDA announced today that it approved Samsung Bioepis' Byooviz injection, making it the first approved biosimilar to Lucentis for treating eye diseases. Byooviz (ranibizumab-nuna) is the first biosimilar to Lucentis (ranibizumab injection). It … [Read More...] about FDA approves first Lucentis injection biosimilar for treating eye diseases
Glaukos announces licensing deal with Attillaps for pharmaceutical compounds
Glaukos (NYSE:GKOS) announced today that it entered into a licensing agreement with Attillaps for its library of pharmaceutical compounds. San Clemente, California-based Glaukos was granted a global exclusive license to research, develop, … [Read More...] about Glaukos announces licensing deal with Attillaps for pharmaceutical compounds
Boston Scientific touts data from Phase 3 study of selective internal radiation therapy
Boston Scientific (NYSE:BSX) today touted data from a Phase 3 clinical trial of its TheraSphere Y-90 glass microspheres treatment. In the trial, the TheraSphere treatment successfully met both primary endpoints, including progression-free survival … [Read More...] about Boston Scientific touts data from Phase 3 study of selective internal radiation therapy
Navidea Biopharmaceuticals makes board of directors changes
Navidea Biopharmaceuticals (NYSE:NAVB) announced today that it made a number of changes on its board of directors. Dublin, Ohio–based Navidea 's chair of the board and director S. Kathryn Rouan, along with director Claudine Bruck, retired from … [Read More...] about Navidea Biopharmaceuticals makes board of directors changes
In case you missed it
- European regulators offer positive opinion on Janssen’s schizophrenia treatment
- Alfred E. Mann Foundation sells insulin infusion pump IP to Medtronic
- Diabeloop joins corporate advisory partnership, seeks to develop business in U.S.
- Pear Therapeutics touts real-world data for reSET-O prescription digital therapeutic
- Philip Morris’ $1.2B offer for inhaled drug delivery tech developer becomes unconditional
- Oramed hits 50% enrollment in Phase 2 trial for oral insulin capsule
- Novo Nordisk Foundation, Harvard, MIT launch research center with focus on diabetes
- Drug delivery tech developer Virpax Pharmaceuticals prices $40M offering
- Gelteq wins U.S. patent for gel-based blood glucose testing platform
- Lyra Therapeutics appoints new CFO
- Lyra touts non-human trial of XTreo drug-eluting implant
- Impel NeuroPharma prices $45M offering following FDA approval for migraine treatment
- Dermavant doses first patient in trial of topical cream for atopic dermatitis
- Better Therapeutics expects $113M SPAC merger to go through in October
- MiMedx confirms shelf registration to sell $350M
Clinical Trials
BD says glass prefillable syringes still perform after deep cold storage
BD (NYSE:BDX) today shared the results from a preliminary study investigating the impact of deep cold storage on glass prefillable syringes. Franklin Lakes, N.J.-based BD’s study evaluated deep cold storage (-20°C and -40°C) as traditional vaccine formulations are commonly stored up to about 2°C to 8°C, while mRNA vaccine formulations (the type of COVID-19 vaccine […]
FDA approves first Lucentis injection biosimilar for treating eye diseases
The FDA announced today that it approved Samsung Bioepis’ Byooviz injection, making it the first approved biosimilar to Lucentis for treating eye diseases. Byooviz (ranibizumab-nuna) is the first biosimilar to Lucentis (ranibizumab injection). It treats several eye diseases and conditions, including neovascular (wet) age-related macular degeneration (nAMD). The treatment involves an intravitreal injection (delivered into […]
Boston Scientific touts data from Phase 3 study of selective internal radiation therapy
Boston Scientific (NYSE:BSX) today touted data from a Phase 3 clinical trial of its TheraSphere Y-90 glass microspheres treatment. In the trial, the TheraSphere treatment successfully met both primary endpoints, including progression-free survival (PFS) and hepatic progression-free survival (hPFS) in patients with metastatic colorectal cancer (mCRC) of the liver. Marlborough, Mass.-based Boston Scientific’s TheraSphere treatment, […]
European regulators offer positive opinion on Janssen’s schizophrenia treatment
Johnson & Johnson’s Janssen Pharmaceutical Companies today announced a positive CHMP opinion on its Byannli schizophrenia treatment. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued the positive opinion. The committee recommended using long-acting atypical antipsychotic Byannli (6-monthly paliperidone palmitate; PP6M) therapy for the maintenance treatment of schizophrenia. […]
Pear Therapeutics touts real-world data for reSET-O prescription digital therapeutic
Pear Therapeutics today announced the publication of positive results from real-world data of its reSET-O prescription digital therapeutic. Boston-based Pear Therapeutics evaluated its FDA-authorized reSET-O PDT in the treatment of opioid use disorder (OUD) on patients treated for 24 weeks, with real-world evidence demonstrating that the treatment is associated with improved outcomes, high levels of […]
